Moreover, we found evidence that human orthologs of mouse susceptible gene signature for ERBB2-driven cancer can be used to not only stratify human patients with BC into distinct prognostic groups independent of clinical factors and PAM50 subtypes across multiple cohorts, but also predict treatment responses independent of the MammaPrint score in the I-SPY2 cohort. The gene discussed is ERBB2; the disease is breast cancer.